Get the Stockscreener App
2.49
2.35%
-0.06
Kiora Pharmaceuticals Inc stock is traded at $2.49, with a volume of 82,384.
It is down -2.35% in the last 24 hours and down -1.58% over the past month.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
See More
Previous Close:
$2.55
Open:
$2.53
24h Volume:
82,384
Relative Volume:
1.51
Market Cap:
$8.55M
Revenue:
-
Net Income/Loss:
$2.81M
P/E Ratio:
-0.1735
EPS:
-14.3497
Net Cash Flow:
$7.14M
1W Performance:
-9.12%
1M Performance:
-1.58%
6M Performance:
-13.24%
1Y Performance:
-28.65%
1-Day Range:
$2.47
$2.62
1-Week Range:
$2.47
$2.80
52-Week Range:
$2.25
$4.18
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
Name
Kiora Pharmaceuticals Inc
Sector
Industry
Phone
858-224-9600
Address
169 SAXONY RD., ENCINITAS
Compare KPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
2.49 | 8.76M | 0 | 2.81M | 7.14M | -14.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.17 | 107.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
471.59 | 64.39B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.86 | 61.13B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
839.80 | 52.30B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
317.51 | 34.99B | 4.56B | -176.77M | 225.30M | -1.7177 |
Kiora Pharmaceuticals Inc Stock (KPRX) Latest News
Kiora Pharmaceuticals Inc Stock Analysis and ForecastResistance Zone Identification & Free Wealth Planning Blueprints - earlytimes.in
Will Kiora Pharmaceuticals Inc. continue its uptrendQuarterly Trade Report & High Win Rate Trade Tips - newser.com
Can Kiora Pharmaceuticals Inc. rally from current levels2025 Market Outlook & High Yield Stock Recommendations - newser.com
How buyback programs support Kiora Pharmaceuticals Inc. (7EY) stock2025 Dividend Review & Real-Time Market Trend Scan - newser.com
How to build a dashboard for Kiora Pharmaceuticals Inc. stockMarket Performance Recap & Low Drawdown Investment Ideas - newser.com
How to track smart money flows in Kiora Pharmaceuticals Inc.July 2025 Closing Moves & Scalable Portfolio Growth Ideas - newser.com
Why global investors buy Kiora Pharmaceuticals Inc. (7EY) stock2025 Macro Impact & Weekly Chart Analysis and Guides - newser.com
Will Kiora Pharmaceuticals Inc. (7EY) stock benefit from commodity supercycle2025 Momentum Check & Free Expert Verified Stock Movement Alerts - newser.com
Is it time to cut losses on Kiora Pharmaceuticals Inc.July 2025 EndofMonth & Risk Controlled Stock Alerts - newser.com
Using Python tools to backtest Kiora Pharmaceuticals Inc. strategiesDay Trade & AI Enhanced Execution Alerts - newser.com
How to build a custom watchlist for Kiora Pharmaceuticals Inc.July 2025 Patterns & Intraday High Probability Setup Alerts - newser.com
What analyst consensus implies for Kiora Pharmaceuticals Inc. (7EY) stockJuly 2025 Patterns & Consistent Profit Alerts - newser.com
What MACD trends signal for Kiora Pharmaceuticals Inc. (7EY) stock2025 Key Lessons & Stepwise Trade Signal Guides - nchmf.gov.vn
Is Kiora Pharmaceuticals Inc. stock bottoming outJuly 2025 Price Swings & Fast Entry Momentum Trade Alerts - newser.com
When is the best time to exit Kiora Pharmaceuticals Inc.Trend Reversal & High Accuracy Buy Signal Tips - newser.com
Applying Wyckoff theory to Kiora Pharmaceuticals Inc. stockShare Buyback & Consistent Return Strategy Ideas - newser.com
Will Kiora Pharmaceuticals Inc. (7EY) stock hit analyst forecastsWeekly Trade Summary & Real-Time Buy Signal Notifications - newser.com
Will Kiora Pharmaceuticals Inc. rebound enough to break evenMarket Activity Summary & Daily Stock Momentum Reports - newser.com
Will Kiora Pharmaceuticals Inc. (7EY) stock justify high valuationJuly 2025 Volume & Weekly High Momentum Picks - nchmf.gov.vn
Will Kiora Pharmaceuticals Inc. stock deliver consistent dividendsQuarterly Profit Report & Pattern Based Trade Signal System - newser.com
Will Kiora Pharmaceuticals Inc. stock outperform value stocksJuly 2025 Macro Moves & Scalable Portfolio Growth Methods - nchmf.gov.vn
Kiora Pharmaceuticals (NASDAQ:KPRX) Stock Price Up 0.4% – Here’s What Happened - Defense World
Analyzing Kiora Pharmaceuticals Inc. with risk reward ratio chartsPortfolio Profit Report & AI Enhanced Trading Alerts - newser.com
Using data filters to optimize entry into Kiora Pharmaceuticals Inc.Quarterly Portfolio Review & Proven Capital Preservation Methods - newser.com
Kiora Pharmaceuticals to Participate in the 2025 Maxim Growth Summit and Eyecelerator @ AAO 2025 - Newsfile
Oct 16 & Oct 22: Kiora Pharmaceuticals to Present Pipeline at Eyecelerator and Maxim Summit - Stock Titan
Tools to monitor Kiora Pharmaceuticals Inc. recovery probability2025 Top Decliners & Weekly Top Gainers Alerts - newser.com
Intraday pattern recognizer results for Kiora Pharmaceuticals Inc.July 2025 Price Swings & Short-Term Swing Trade Alerts - newser.com
Is Kiora Pharmaceuticals Inc. stock ready for a breakout2025 Trading Volume Trends & Fast Gain Stock Trading Tips - newser.com
Can Kiora Pharmaceuticals Inc. stock double in next 5 yearsGap Down & Free AI Powered Buy and Sell Recommendations - newser.com
Will earnings trigger a reversal in Kiora Pharmaceuticals Inc.Portfolio Gains Report & Proven Capital Preservation Methods - newser.com
Kiora Pharmaceuticals Inc Stock (KPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.25%
1.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):